- Home
- EPAC vs IMCR Comparison
EPAC vs IMCR Comparison
Compare EPAC & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPAC
- IMCR
- Stock Information
- Founded
- EPAC 1910
- IMCR 2008
- Country
- EPAC United States
- IMCR United Kingdom
- Employees
- EPAC N/A
- IMCR N/A
- Industry
- EPAC Industrial Machinery/Components
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EPAC Technology
- IMCR Health Care
- Exchange
- EPAC Nasdaq
- IMCR Nasdaq
- Market Cap
- EPAC 2.4B
- IMCR 1.7B
- IPO Year
- EPAC N/A
- IMCR 2021
- Fundamental
- Price
- EPAC $44.59
- IMCR $32.93
- Analyst Decision
- EPAC Strong Buy
- IMCR Buy
- Analyst Count
- EPAC 1
- IMCR 14
- Target Price
- EPAC $35.00
- IMCR $74.75
- AVG Volume (30 Days)
- EPAC 388.1K
- IMCR 267.8K
- Earning Date
- EPAC 10-15-2024
- IMCR 11-05-2024
- Dividend Yield
- EPAC 0.09%
- IMCR N/A
- EPS Growth
- EPAC 91.76
- IMCR N/A
- EPS
- EPAC 1.56
- IMCR N/A
- Revenue
- EPAC $589,510,000.00
- IMCR $280,914,000.00
- Revenue This Year
- EPAC $10.55
- IMCR $25.60
- Revenue Next Year
- EPAC $5.46
- IMCR $10.63
- P/E Ratio
- EPAC $28.46
- IMCR N/A
- Revenue Growth
- EPAC N/A
- IMCR 27.95
- 52 Week Low
- EPAC $27.06
- IMCR $29.72
- 52 Week High
- EPAC $45.17
- IMCR $76.98
- Technical
- Relative Strength Index (RSI)
- EPAC 63.60
- IMCR 52.76
- Support Level
- EPAC $44.07
- IMCR $31.10
- Resistance Level
- EPAC $45.17
- IMCR $35.47
- Average True Range (ATR)
- EPAC 1.20
- IMCR 1.49
- MACD
- EPAC 0.03
- IMCR 0.17
- Stochastic Oscillator
- EPAC 91.78
- IMCR 51.98
About EPAC Enerpac Tool Group Corp.
Enerpac Tool Group, previously known as Actuant, provides high-precision tools, controlled-force products, and solutions for precise heavy lifting. The company operates through two segments: industrial tools and services and other. It categorizes its revenue into two parts: product sales and services, which include manpower services and rentals. Product sales is the largest contributor to the company's total revenue. Geographically, the company operates in the United States, Asia, Australia, Europe, Middle East, and other areas. The U.S. makes up the largest contribution to the company's total revenue.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.